Antibodies to her

FIELD: biotechnologies.

SUBSTANCE: invention describes versions of bispecific antibodies specifically bound to EGFR and HER3, which contain amino-acid sequences of variable regions of heavy and light chains respectively, SEQ ID NO: 30 and 29; or SEQ ID NO: 28 and 27; or SEQ ID NO: 28 and 29; or contain complementary regions CDR of heavy and light chains of the above sequences of variable regions. The invention describes nucleic acid coding a versions antibody, and a host cell containing the above nucleic acid and used for expression of the anitbody. Immunoconjugate containing antibody versions and cytotoxic agent used for treatment of cancer containing cells that express EGFR and HER3 are presented. A method for obtaining a bispecific antibody, which involves cultivation of a host cell so that an antibody is generated, is described. The invention describes a pharmaceutical composition for treatment of cancer containing EGFR- and HER3-expressing cells, which contains effective amount of bispecific antibody and pharmaceutically acceptable carrier. The invention proposes a treatment method of cancer containing EGFR- and HER3-expressing cells and an inhibition method of biological activity of EGFR and/or HER3 of a specimen, which involve introduction of effective amount of a bispecific antibody. Use of the above antibody in production of a remedy for treatment of cancer, the cells of which express EGFR and HER3, is described.

EFFECT: invention allows obtaining bispecific antibodies binding EGFR and HER3, which are not conjugates of two antibodies.

22 cl, 33 dwg, 4 tbl, 19 ex

 

The text descriptions are listed faxing

1. Selected bispecific antibody containing the sequence of the variable domain of the heavy chain SEQ ID NO: 30 and the sequence of the variable domain of the light chain of SEQ ID NO: 29, where the antibody specifically binds to EGFR and HER3,.

2. Selected bispecific antibody, comprising antig nswazwi domain, which specific binds to EGFR and HER3, where the antibody includes
(a) HVR-H1 containing the amino acid sequence LSGDWIH (SEQ ID NO: 48);
(b) HVR-H2 containing the amino acid sequence VGEISAAGGYTD (SEQ ID NO: 51); and
(c) HVR-H3 containing the amino acid sequence ARESRVSFEAAMDY (SEQ ID NO: 53); and
(d) HVR-L1 containing the amino acid sequence NIATDVA (SEQ ID NO: 55);
(e) HVR-L2 containing the amino acid sequence SASF (SEQ ID NO: 56); and
(f) HVR-L3 containing the amino acid sequence SEPEPYT (SEQ ID NO: 57).

3. Selected bispecific antibody comprising antigennegative domain that is specific binds to EGFR and HER3, where the antibody includes
(a) HVR-H1 containing the amino acid sequence LSGDWIH (SEQ ID NO: 48);
(b) HVR-H2 containing the amino acid sequence LGEISAAGGYTD (SEQ ID NO: 50); and
(c) HVR-H3 containing the amino acid sequence ARESRVSFEAAMDY (SEQ ID NO: 53); and
(d) HVR-L1 containing the amino acid sequence DLATDV (SEQ ID NO: 54);
(e) HVR-L2 containing the amino acid sequence SASF (SEQ ID NO: 56); and
(f) HVR-L3 containing the amino acid sequence SEPEPYT (SEQ ID NO: 57).

4. Selected bispecific antibody comprising antigennegative domain that is specific binds to EGFR and HER3, where the antibody includes
(a) HVR-H1 containing the amino acid sequence LSGDWIH (SEQ ID NO: 48);
(b) HVR-H2, and containing inoculate sequence LGEISAAGGYTD (SEQ ID NO: 50); and
(c) HVR-H3 containing the amino acid sequence ARESRVSFEAAMDY (SEQ ID NO: 53); and
(d) HVR-L1 containing the amino acid sequence NIATDVA (SEQ ID NO: 55);
(e) HVR-L2 containing the amino acid sequence SASF (SEQ ID NO: 56); and
(f) HVR-L3 containing the amino acid sequence SEPEPYT (SEQ ID NO: 57).

5. Selected bispecific antibody containing the sequence of the variable domain of the heavy chain SEQ ID NO: 28 and sequence of the variable domain of the light chain of SEQ ID NO: 27, where the antibody specifically binds to EGFR and HER3,.

6. Selected bispecific antibody containing the sequence of the variable domain of the heavy chain SEQ ID NO: 28 and sequence of the variable domain of the light chain of SEQ ID NO: 29, where the antibody specifically binds to EGFR and HER3,.

7. The antibody according to any one of claims 1 to 6, where the antibody is a full-sized antibody IgG1.

8. The antibody according to claim 7, where the antibody exhibits ADCC activity.

9. The antibody according to any one of claims 1 to 8 for use as drugs for the treatment of cancer where the cancer comprises cells that Express EGFR and HER3,.

10. The antibody according to any one of claims 1 to 8 for use in the treatment of cancer where the cancer comprises cells that Express EGFR and HER3,.

11. The antibody according to claim 9 or 10, where the cancer is selected from the group consisting of breast cancer, colorectal cancer, pancreatic cancer is elezi, head and neck cancer, melanoma, ovarian cancer, prostate cancer and non-small cell lung cancer.

12. The selected nucleic acid encoding the antibody according to any one of claims 1 to 8.

13. A host cell containing the nucleic acid according to item 12, where the cell is capable of expressionate exogenous genetic material.

14. A method of producing an antibody comprising culturing the host cell according to item 13 so that the produced antibody.

15. Immunoconjugate containing the antibody according to any one of claims 1 to 8 and cytotoxic agent for use in the treatment of cancer where the cancer comprises cells that Express EGFR and HER3,.

16. Pharmaceutical composition comprising an effective amount of the antibody according to any one of claims 1 to 8 and a pharmaceutically acceptable carrier, for use in the treatment of cancer where the cancer comprises cells that Express EGFR and HER3,.

17. The method of treatment of a subject suffering from cancer comprising the administration to a subject an effective amount of the antibody according to any one of claims 1 to 8, wherein the cancer comprises cells that Express EGFR and HER3,.

18. The method according to 17, where the cancer is selected from the group consisting of breast cancer, colorectal cancer, pancreatic cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer and non-small cell lung cancer.

19. How inhibi the Finance biological activity of EGFR and/or HER3, the subject, includes introduction to the subject an effective amount of the antibody according to any one of claims 1 to 8 for inhibition of biological activity of EGFR and/or HER3,.

20. The antibody according to any one of claims 1 to 8 for use in the inhibition of the biological activity of EGFR and/or HER3,.

21. The use of antibodies according to any one of claims 1 to 8 in the manufacture of medicaments for the treatment of cancer where the cancer comprises cells that Express EGFR and HER3,.

22. Use item 21, where the cancer is selected from the group consisting of breast cancer, colorectal cancer, pancreatic cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer and lung cancer.



 

Same patents:

FIELD: biotechnologies.

SUBSTANCE: two antibodies against IL-21 of a human being are presented. The first antibody includes a variable region of a heavy chain, which includes SEQ ID NO: 31, 33 and 35, and a variable region of a light chain, which includes SEQ ID NO: 39, 41 and 43. The second antibody includes a variable region of heavy chain, which includes SEQ ID NO: 47, 49 and 51, and variable region of light chain, which includes SEQ ID NO: 55, 57 and 59. Besides, the invention describes hybridomes producing the first and the second antibodies against IL-21 of a human being and deposited in the collection of cultures "American Type Culture Collection" and have numbers "ATCC Patent Deposit Designation PTA-8790" and "ATCC Patent Deposit Designation PTA-8786" respectively.

EFFECT: invention allows obtaining antibodies to IL-21 of a human being.

48 cl, 4 dwg, 16 tbl, 23 ex

FIELD: biotechnologies.

SUBSTANCE: method involves introduction to a plant, some part of the plant or a plant cell of nucleotide sequence for 80-100% of identical nucleotide sequence determined in SEQ ID NO: 17, and coding a composite protein containing a cytoplasmic end segment, a transmembrane domain, a steam area (CTS domain) of N-acetylglucosaminyl transferase (GNT1), which is merged with catalytic domain of beta-1,4-galactosyl transferase (GalT); with that, the above first nucleotide sequence is functionally connected to the first regulatory area being active in the plant; and the second nucleotide sequence for coding of a target protein; with that, the above second nucleotide sequence is functionally connected to the second regulatory area being active in the plant, as well as transient co-expression of the first and the second nucleotide sequences with synthesis of the target protein containing glycans, with reduced xylosylation, reduced fucosylation or their combination at comparison to the same target protein obtained from a wild plant. The invention described nucleic acid coding the protein that modifies glycosylation of target protein, a composite protein for modification of glycosylation of target protein; nucleic acid that codes it, as well as a plant, a plant cell and a seed, which contain the above nucleic acid or the above composite protein.

EFFECT: invention allows effective production of a target protein with reduced xylosylation, reduced fucosylation or their combination.

20 cl, 7 dwg, 9 ex

FIELD: biotechnologies.

SUBSTANCE: invention proposes variable domains of heavy (VH) and light (VL) chains of murine antibody against tumour necrosis factor alpha (TNF-α) of a human being, as well as antigen-binding fragment Fab, which are selectively bound to TNF-α of the human being and neutralise it.

EFFECT: invention can be further used in development of medicines for therapy of TNF-α-mediated diseases and for diagnostics of such diseases.

3 cl, 5 tbl, 7 ex

FIELD: biotechnologies.

SUBSTANCE: invention relates to a molecule of nucleic acid, which is a cyclic or a linear vector fit for expression, of at least one target polypeptide in cells of mammals, including (a) at least one expressing cassette (POI) for expression of the target polypeptide; (b) an expressing cassette (MSM), including a gene of a selective marker of mammals; (c) an expressing cassette (MASM), including an amplificated gene of a selective marker of mammals; besides, the expressing cassette (POI) is flanked in direction 5' by the expression cassette (MASM), the expression cassette (MSM) is localised in direction 3' from the expression cassette (POI) and in which the expression cassettes (MASM), (POI) and (MSM) are arranged in the same orientation from 5' to 3'. Also the method is disclosed to produce the specified molecule of nucleic acid of the vector, as well as a cell of a host mammal, containing the specified molecule of nucleic acid of the vector, the method to produce a host cell containing the specified molecule of nucleic acid of the vector, and also the method to produce the target polypeptide, using the specified host cell.

EFFECT: invention makes it possible to efficiently produce a target polypeptide in mammal cells.

24 cl, 2 dwg, 4 tbl, 13 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology and immunology. There are presented: a method for tumour cell growth inhibition in an individual and a method for immune response enhancement in an individual involving the introduction of a PD-1 monoclonal antibody and a CTLA-4 10D1 monoclonal antibody to the individual. The PD-1 monoclonal antibody has the following properties: it binds to human PD-1 having the value KD equal to 1×10-8 M or less; however it binds neither to human CD28, nor to CTLA-4, nor to ICOS; it is able to enhance the T-cell proliferation in the mixed lymphocyte reaction (MLR) analysis; it is able to enhance the gamma interferon production in the MLR analysis; it is able to enhance the interleukine-2 (IL-2) secretion in the MLR analysis.

EFFECT: invention provides a synergic effect when using the above antibodies in a combination.

4 cl, 54 dwg, 7 tbl, 25 ex

Novel antibodies // 2490277

FIELD: chemistry.

SUBSTANCE: present invention relates to immunology. Disclosed is an anti-α5β1 antibody, which is described through amino acid sequences of six hypervariable regions and an antigen-binding moiety thereof. Described are conjugates of the disclosed antibodies with a medicinal agent or a label, a pharmaceutical composition, use of the disclosed antibodies to prepare a medicinal agent, methods and an industrial product for inhibiting angiogenesis and/or vascular permeability in a subject, and for treating cancer, an ophthalmic disease and an autoimmune disease in a subject. The invention describes an isolated nucleic acid, an expression vector, a cell and a method of producing an antibody or an antigen-binding moiety thereof, as well as a method of detecting α5β1 protein in a sample.

EFFECT: present invention can find further use in therapy and diagnosis of α5β1-mediated diseases.

52 cl, 11 dwg, 6 ex

FIELD: chemistry.

SUBSTANCE: disclosed are versions of human IL13 specific antibodies and a producing hybridoma cell line deposited in ATCC under number PTA-5657. Described are: versions of encoding polynucleotides; an antibody expression vector; a host cell for antibody expression, as well as versions of a method of producing an antibody using a vector, polynucleotide, hybridoma or host cell. The invention discloses a pharmaceutical composition for treating IL13-mediated diseases and methods of treating allergic, inflammatory and other diseases, which employ an anti-IL13 antibody.

EFFECT: providing antibodies which do not bind with target IL13 and neutralise activity of human IL13.

39 cl, 29 dwg, 11 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology, more specifically to expression constructs, and may be used for immunoglobulin expression. An expression vector contains one open reading frame (sORF) insert which contains a first sequence of nucleic acid coding a first polypeptide; a first intermediate sequence of nucleic acid coding a first protein cleavage site containing an autoprocessing element with an intein segment providing proteolytic sORF polypeptide cleavage between the first polypeptide and the intein segment and the second polypeptide, but not ligation of said first polypeptide with said second polypeptide; and a second sequence of nucleic acid coding the second polypeptide. The expression vector is able to express a mammalian polypeptide coding sORF and cleaved in said first protein cleavage site in a host cell; consisting of the first polypeptide - an immunoglobulin heavy chain, and the second polypeptide - an immunoglobulin light chain able to be assembled into a multimer.

EFFECT: invention provides functional antibody production with 'correct' setup and assembly.

40 cl, 9 dwg, 57 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology and can be used to obtain monoclonal antibodies against the Yersinia pestis V antigen. The strain of hybrid animal cells Mus musculus 2B8 is obtained by immunising BALB/c mice. The mice are immunised by four-time administration of a recombinant V antigen in a dose of 100 mcg/mouse. On the third day after the last immunication, splenocytes of immune mice (1×108 cells) are hybridised with mouse myeloma cells RZ-X63 Ag/8-653 (1×107 cells). The fusion agent used is polyethylene glycol (Sigma, USA). Hybridisation is followed by selection, screening, cloning and cryopreservation of the hybridoma. The strain is deposited in the state collection of pathogenic microorganisms and cell cultures (GKPM-Obolensk) under number N-20.

EFFECT: strain of hybrid cultured cells, which produces monoclonal antibodies which are specific to the Y pestis V antigen, is suitable for constructing test systems for detecting plague pathogens.

8 dwg, 3 tbl, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology and can be used to obtain monoclonal antibodies against the Yersinia pestis V antigen. The strain of hybrid animal cells Mus musculus 5G6 is obtained by immunising BALB/c mice. The mice are immunised by four-time administration of a recombinant V antigen in a dose of 100 mcg/mouse. On the third day after the last immunication, splenocytes of immune mice (1×108 cells) are hybridised with mouse myeloma cells RZ-X63 Ag/8-653 (1×107 cells). The fusion agent used is polyethylene glycol (Sigma, USA). Hybridisation is followed by selection, screening, cloning and cryopreservation of the hybridoma. The strain is deposited in the state collection of pathogenic microorganisms and cell cultures (GKPM-Obolensk) under number N-19.

EFFECT: strain of hybrid cultured cells, which produces monoclonal antibodies which are specific to the Y pestis V antigen, is suitable for constructing test systems for detecting plague pathogens.

8 dwg, 2 tbl, 7 ex

FIELD: biotechnologies.

SUBSTANCE: invention describes polynucleotide, expression vector, host cell and production method of humanised antibody together with their use, as well as medical preparation against rheumatoid arthritis, prophylaxis or treatment method of rheumatoid arthritis and use of humanised antibody at production of pharmaceutical preparation for prophylaxis or treatment of rheumatoid arthritis. This invention can be used in therapy of human diseases associated with α9 integrin.

EFFECT: improved activity and thermal stability.

14 cl, 6 dwg, 6 tbl, 11 ex

FIELD: biotechnologies.

SUBSTANCE: invention proposes humanised anti-NKG2A antibody obtained from murine antibody Z270, which is characterised through amino-acid sequences of variable domains, and method of its obtainment. Besides, a pharmaceutical composition is described, which contains an antibody according to the invention, a treatment method and application of the antibody in production of a medicine to be injected into a patient who is a human being suffering the disorder chosen from cancer, virus disease, inflammatory disorder and autoimmune disorder.

EFFECT: invention can be further used in therapy.

14 cl, 20 dwg, 2 tbl, 16 ex

FIELD: chemistry.

SUBSTANCE: disclosed is a method of purifying antibodies, including human CD20 and VEGF binding antibodies, from a composition which contains an antibody and at least one impurity compound, said method comprising the following steps: (a) loading the composition on a cation-exchange material, where said composition has first pH value from 4.0 to 6.0; (b) washing the cation-exchange material with a first washing buffer at pH higher than that of composition (a), where pH of the first washing buffer ranges from 6.8 to 9.0; (c) washing the cation-exchange material with a second washing buffer at pH lower than that of the first washing buffer; where the second washing buffer has conductivity from 0.5 to 3.0 mS/cm and pH from 5.0 to 6.0; and (d) elution of the antibodies from the cation-exchange material with an elution buffer at conductivity which is at least 2 mS/cm higher than that of the second washing buffer, where pH of the second washing buffer and pH of the elution buffer are approximately equal, and where pH of the elution buffer ranges from 5.0 to 6.0. Described is a conjugation method, which involves conjugating the purified product obtained using said method with a heterologous molecule. Also disclosed is a method of producing a pharmaceutical composition, which involves combining said purified product with a pharmaceutically acceptable carrier.

EFFECT: invention improves purification of antibodies used for treatment.

16 cl, 3 dwg, 4 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to immunology. What is presented is a humanized human monoclonal CD19 antibody prepared of an HB12B antibody, or a fragment thereof characterised by amino acid sequences of variable domains. Also, there are presented nucleic acids coding polypeptides having the sequences of the variable domains, and a cell expressing the antibody under the invention, and a pharmaceutical composition, and a method for treating a B-cell diseases or disorders in a human.

EFFECT: invention can find further application in treating various CD19-associated diseases, including autoimmune diseases, and preventing or treating the graft-versus-host disease (GVHD), and the humoral rejection and post-transplantation lymphoproliferative disorder in a human graft recipient.

21 cl, 45 dwg, 40 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to biochemistry and immunology. What is considered is an isolated antibody molecule which binds an alpha chain of human granulocyte/macrophage colony stimulating factor receptor (GM-CSFRα) and inhibits GM-CSF binding to human GM-CSFRα. There are presented: a composition for GM-CSFRα inhibition or neutralisation and a composition for treating rheumatoid arthritis, asthma, chronic obstructive pulmonary disease or myeloid leukaemia, containing the antibody under the invention; the isolated nucleic acid molecule coding the antibody under the invention, a host cell and a method for preparing the antibody under the invention, as well a method for inhibiting or neutralising GM-CSFRα activity and a method of treating rheumatoid arthritis, asthma, chronic obstructive pulmonary disease or myeloid leukaemia in a patient.

EFFECT: invention can find further application in therapy of the GM-CSFRα-mediated diseases.

41 cl, 5 tbl, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology and immunology. There are presented: a method for tumour cell growth inhibition in an individual and a method for immune response enhancement in an individual involving the introduction of a PD-1 monoclonal antibody and a CTLA-4 10D1 monoclonal antibody to the individual. The PD-1 monoclonal antibody has the following properties: it binds to human PD-1 having the value KD equal to 1×10-8 M or less; however it binds neither to human CD28, nor to CTLA-4, nor to ICOS; it is able to enhance the T-cell proliferation in the mixed lymphocyte reaction (MLR) analysis; it is able to enhance the gamma interferon production in the MLR analysis; it is able to enhance the interleukine-2 (IL-2) secretion in the MLR analysis.

EFFECT: invention provides a synergic effect when using the above antibodies in a combination.

4 cl, 54 dwg, 7 tbl, 25 ex

FIELD: biotechnologies.

SUBSTANCE: antagonistic antibody is proposed, which specifically binds with a conformational epitope from a fragment 1378-1640 of an amino acid sequence Notch3, given in the description, and inhibits activation of Notch3. The specified antibody is characterised by the fact that it contains variable areas of light and heavy chain, with a set of appropriate CDR1-CDR3, amino acid sequences of which are given in the description. An antibody may additionally contain a mark. The following is proposed: versions of a coding nucleic acid, an expressing vector, a cell for antibody production, containing the specified vector. The method is described to produce antibodies by means of cell cultivation. Versions of antibodies application are disclosed: to detect a disease related to Notch3, for production of a medicinal agent for treatment of an individual with a disorder or a disease related to Notch3, for treatment of Notch3-related disease or disorder.

EFFECT: using the invention may find application in medicine in treatment or prevention of Notch3-related diseases or disorders.

25 cl, 18 dwg, 4 tbl, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to immunology. What is presented is a low-immunogenicity anti-CD40 monoclonal antibody prepared of a chimeric 5D12 (ch5D12) antibody. There are also described: a nucleic acid, a cell and a cell culture for preparing the antibody according to the invention, a method for preparing it, a pharmaceutical composition, using the antibody for preparing a drug and a method for administering the antibody according to the invention to an individual for the purpose of relieving the symptoms of an autoimmune disease, an inflammatory disease, for the purpose of suppressing a graft rejection reaction and/or treating CD40-positive cancer.

EFFECT: what is described is a method for selecting the high-expression human anti-CD40 antibodies containing insertion, deletion, inversion and/or replacement of 1 to 5 amino acids as compared to the antibody according to the invention, and the antibody prepared by the above method for selecting.

31 cl, 21 dwg, 14 tbl, 10 ex

FIELD: chemistry.

SUBSTANCE: claimed invention relates to field of biotechnology and immunology. Claimed is antibody, specifically binding with form A FcγRIII (CD16) (FcγRIIIA, CD16A) and not-binding specifically with form B (FcγRIIIB, CD16B), its antigen-binding fragment and multi-specific antibody, which includes antigen-binding fragment of antibody by invention. Compositions, which contain antibody by invention or its antigen-binding fragment, and their application in treatment of autoimmune, inflammatory, inflectious diseases, allergy and cancer, as well as set for detection of FcγRIIIA are described. Polynucleotides, vectors and host cells and method of obtaining antibody by invention or its antigen-binding fragment are described.

EFFECT: claimed invention provides novel antibodies to FcγRIIIA and, in that way, can find further application in therapy of FcγRIIIA-mediated diseases.

51 cl, 24 ex, 8 dwg, 5 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to biochemistry and discloses an isolated antibody which specifically binds a human interleukin-4 receptor α (hlL-4Ra). The antibody includes a VH antibody domain which contains a set of CDR: HCDR1, HCDR2, HCDR3 and a framework region, and a VL antibody domain containing a set of CDR: LCDR1, LCDR2 and LCDR3 and a framework region, wherein the set of CDR has 10 or less substitutions of amino acids selected from the set of CDR, where: HCDR1 is characterised by amino acid sequence SEQ ID NO:193; HCDR2 is characterised by amino acid sequence SEQ ID NO:194; HCDR3 is characterised by amino acid sequence SEQ ID NO:195; LCDR1 is characterised by amino acid sequence SEQ ID NO:198; LCDR2 is characterised by amino acid sequence SEQ ID NO:199; and LCDR3 is characterised by amino acid sequence SEQ ID NO:200, and where the substitutions do not result in loss of the capability to bind hIL-4Ra.

EFFECT: invention broadens the range of antibodies that specifically bind interleukin-4 receptor α.

15 cl, 17 dwg, 7 tbl, 5 ex

FIELD: biotechnologies.

SUBSTANCE: invention proposes an antibody that specifically binds heparin-binding EGF-like growth factor (HB-EGF) and its antigen-binding fragment. Invention describes a nucleic acid molecule, an expressing vector, a host cell and a method for obtaining an antibody or its antigen-binding fragment, as well as use of antibody or its antigen-binding fragment for obtaining pharmaceutical composition for diagnostics, prevention or treatment of hyperproliferation disease, methods and sets for diagnostics and prevention or treatment of the state associated with HB-EGF expression. This invention can be further found in therapy of diseases determined with or related to HB-EGF expression.

EFFECT: improving efficiency of composition and treatment method.

34 cl, 43 dwg, 28 ex, 12 tbl

Up!